The importance of norepinephrine in depression

Neuropsychiatric Disease and Treatment

Volumn 7, Issue SUPPL., 2011, Pages 9-13

  Moret, Chantal ^a   Briley, Mike ^a  

^a NeuroBiz Consulting and Communication   (France)

Author keywords

Antidepressants; Neurotransmission; Serotonin; Symptoms

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR; DESIPRAMINE; DOPAMINE; DULOXETINE; MILNACIPRAN; NORADRENALIN; NORTRIPTYLINE; REBOXETINE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; BRAIN FUNCTION; COGNITION; DECISION MAKING; DEPRESSION; DRUG EFFICACY; EMOTION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HORMONE ACTION; HUMAN; LIMBIC SYSTEM; MOTIVATION; NEUROANATOMY; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENERGIC SYSTEM; PATHOGENESIS; PROTEIN DEPLETION; QUALITY OF LIFE; SOCIAL BEHAVIOR; SOCIAL DISABILITY; WORKING MEMORY;

EID: 80955124144     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S19619     Document Type: Article

References (50)

1. JL. Depression. http://emedicine.medscape.com/article/286759-overview (2010).
2. United States Surgeon General. Mental Health: A Report of the Surgeon General - Chapter 2 The fundamentals of mental health and mental illness 1999. Available from: http://www.surgeongeneral.gov/library/ mentalhealth/pdfs/c2.pdf. Accessed April 11, 2011.
3. Videbech P, Ravnkilde B. Hippocampal volume and depression: a metaanalysis of MRI studies. Am J Psychiatry. 2004;161:1957-1966.
4. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008;64:527-532.
5. Monteleone P. Endocrine disturbances and psychiatric disorders. Curr Opin Psychiatry. 2001;14:605-610.
6. Cutter WJ, Norbury R, Murphy DG. Oestrogen, brain function, and neuropsychiatric disorders. J Neurol Neurosurg Psychiatry. 2003; 74:837-840.
7. Douma SL, Husband C, O'Donnell ME, Barwin BN, Woodend AK. Estrogen-related mood disorders reproductive life cycle factors. Adv Nurs Sci. 2005;28:364-375.
8. Lasiuk GC, Hegadoren KM. The effects of estradiol on central serotonergic systems and its relationship to mood in women. Biol Res Nurs. 2007;9:147-160.
9. Estrada-Camarena E, López-Rubalcava C, Vega-Rivera N, Récamier-Carballo S, Fernández-Guasti A. Antidepressant effects of estrogens: a basic approximation. Behav Pharmacol. 2010;21: 451-464.
10. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46-56.
11. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446-457.
12. Perović B, Jovanovic ́ M, Miljković B, Vezmar S. Getting the balance right: established and emerging therapies for major depressive disorders. Neuropsychiatr Dis Treat. 2010;6:343-364.
13. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358:55-68.
14. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455:894-902.
15. Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 2008;69 Suppl E1:4-7.
16. Marin H, Menza MA. The management of fatigue in depressed patients. Essent Psychopharmacol. 2005;6:185-192.
17. Cowen PJ. Serotonin and depression: pathophysiological mechanism or marketing myth? Trends Pharmacol Sci. 2008;29:433-436.
18. Delgado PL, Moreno FA. Role of norepinephrine in depression. J Clin Psychiatry. 2000;61 Suppl 1:5-12.
19. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007;64:327-337.
20. Montgomery SA. The under-recognized role of dopamine in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2008;23:63-69.
21. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. New York, NY: Cambridge University Press; 2008.
22. Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol. 2002; 12:527-544.
23. Stahl SM. Symptoms and circuits, part 1: major depressive disorder. J Clin Psychiatry. 2003;64:1282-1283.
24. Stahl SM, Zhang L, Damatarca C, Grady M. Brain circuits determine destiny in depression: a novel approach to psychopharmacology of wakefulness, fatigue and executive dysfunction in major depressive disorder. J Clin Psychiatry. 2003;64(Suppl 14):6-17.
25. Stahl SM. Symptoms and circuits, part 3: schizophrenia. J Clin Psychiatry. 2004;65:8-9.
26. Stahl SM. Brainstorms: symptoms and circuits, part 2: anxiety disorders. J Clin Psychiatry. 2003;64:1408-1409.
27. Papazian O, Alfonso I, Luzondo RJ. Executive function disorders. Rev Neurol. 2006;42 Suppl 3:S45-S50.
28. Briley M, Moret C. Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors. Neuropsychiatr Dis Treat. 2010;6:647-655.
29. Mann JJ, Stanley M, McBride PA, McEwen BS. Increased serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry. 1986;43:954-959.
30. Ordway GA, Schenk J, Stockmeier CA, May W, Klimek V. Elevated agonist binding to alpha 2-adrenoceptors in the locus coeruleus in major depression. Biol Psychiatry. 2003;53:315-323.
31. Escribá PV, Ozaita A, García-Sevilla JA. Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology. 2004;29: 1512-1521.
32. Valdizán EM, Díez-Alarcia R, González-Maeso J, et al. α(2)- Adrenoceptor functionality in postmortem frontal cortex of depressed suicide victims. Biol Psychiatry. 2010;68:869-872.
33. Klimek V, Stockmeier C, Overholser J, et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci. 1997;17:8451-8458.
34. Gurguis GN, Vo SP, Griffith JM, Rush AJ. Platelet alpha2A-adrenoceptor function in major depression: Gi coupling, effects of imipramine and relationship to treatment outcome. Psychiatry Res. 1999;89: 73-95.
35. Maes M, Van Gastel A, Delmeire L, Meltzer HY. Decreased platelet alpha-2 adrenoceptor density in major depression: effects of tricyclic antidepressants and fluoxetine. Biol Psychiatry. 1999;45:278-284.
36. Wang YM, Xu F, Gainetdinov RR, Caron MG. Genetic approaches to studying norepinephrine function: knockout of the mouse norepinephrine transporter gene. Biol Psychiatry. 1999;46:1124-1130.
37. Haenisch B, Bilkei-Gorzo A, Caron MG, Bönisch H. Knockout of the norepinephrine transporter and pharmacologically diverse antidepressants prevent behavioral and brain neurotrophin alterations in two chronic stress models of depression. J Neurochem. 2009;111: 403-416.
38. Lin Z, Madras BK. Human genetics and pharmacology of neurotransmitter transporters. Handb Exp Pharmacol. 2006;175:327-371.
39. Ono H, Shirakawa O, Nushida H, Ueno Y, Maeda K. Association between catechol-O-methyltransferase functional polymorphism and male suicide completers. Neuropsychopharmacology. 2004;29:1374-1377.
40. Ohara K, Nagai M, Suzuki Y, Ohara K. Low activity allele of catechol-omethyltransferase gene and Japanese unipolar depression. Neuroreport. 1998;9:1305-1308.
41. Frisch A, Postilnick D, Rockah R, et al. Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways. Mol Psychiatry. 1999;4:389-392.
42. Kunugi H, Vallada HP, Hoda F, et al. No evidence for an association of affective disorders with high- or low-activity allele of catechol-omethyltransferase gene. Biol Psychiatry. 1997;42:282-285.
43. Berman RM, Narasimhan M, Miller HL, et al. Transient depressive relapse induced by catecholamine depletion: potential phenotypic vulnerability marker? Arch Gen Psychiatry. 1999;56:395-403.
44. Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry. 2007;12:331-359.
45. Nutt D, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol. 2007;21:461-471.
46. Massana J. Reboxetine versus fluoxetine: an overview of efficacy and tolerability. J Clin Psychiatry. 1998;59 Suppl 14:8-10.
47. Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol. 1997;11(4 Suppl):S9-S15.
48. Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ. 2010;341:c4737.
49. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007;62:1217-1227.
50. C. Understanding neurotransmission in the brain. Available from: http://www.psy-world.com/unt_noradr.htm. Accessed December 14, 2010.